Amarin (AMRN)
(Delayed Data from NSDQ)
$0.59 USD
-0.01 (-1.80%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $0.60 +0.01 (1.16%) 7:20 PM ET
1-Strong Buy of 5 1
B Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.59 USD
-0.01 (-1.80%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $0.60 +0.01 (1.16%) 7:20 PM ET
1-Strong Buy of 5 1
B Value B Growth F Momentum C VGM
Zacks News
Amarin (AMRN) Q1 Earnings Top, Vascepa Sales Hit by COVID-19
by Zacks Equity Research
Amarin's (AMRN) Vascepa sales get hit by COVID-19 and by severe winter storms and power outages in various areas of the United States. Its cost management plan boost the bottom line. Stock up.
Amarin (AMRN) Q4 Earnings & Revenues Top, Vascepa Sales Solid
by Zacks Equity Research
Amarin's (AMRN) revenue growth in the fourth quarter is attributable to continued demand for its cardiovascular drug, Vascepa.
Amarin (AMRN) Surges: Stock Moves 9% Higher
by Zacks Equity Research
Amarin (AMRN) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Is the Options Market Predicting a Spike in Amarin (AMRN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Amarin's (AMRN) Q3 Earnings Lag, Sales In Line, Stock Down
by Zacks Equity Research
Amarin's (AMRN) revenue growth in the third quarter is attributable to continued demand for its cardiovascular drug, Vascepa. Generic competition for Vascepa seems imminent.
Are Options Traders Betting on a Big Move in Amarin (AMRN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Biotech Stock Roundup: GILD Submits BLA, ALBO Gains on Study Data & More
by Zacks Equity Research
The biotech sector remains in focus with regulatory and other pipeline updates.
Amarin Loses Patent Appeal in Vascepa Lawsuit, Stock Dips
by Zacks Equity Research
Amarin (AMRN) receives a setback as the U.S. Court of Appeals upholds a ruling by Nevada district court in favor of the generic companies related to patent litigation against Vascepa.
Are Options Traders Betting on a Big Move in Amarin (AMRN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Amarin (AMRN) in Focus: Stock Moves 5.5% Higher
by Zacks Equity Research
Amarin (AMRN) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Amarin (AMRN) Beats on Q2 Earnings, Focuses on Europe
by Zacks Equity Research
Amarin's (AMRN) revenue growth in the second quarter is attributable to continued demand for its cardiovascular drug, Vascepa.
Zomedica (ZOM) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Zomedica (ZOM) will provide an update on Truforma, its inaugural point-of-care diagnostic biosensor platform, when it reports second-quarter 2020 results
Aytu (AYTU) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Aytu (AYTU) will provide financial updates when it reports fourth-quarter fiscal 2020 results.
Amneal (AMRX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Amneal (AMRX) will provide financial updates when it reports second-quarter 2020 results.
Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis (ZTS) will provide financial updates when it reports second-quarter 2020 results.
Amarin (AMRN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Amarin (AMRN) closed at $7.03, marking a +1.59% move from the previous day.
Implied Volatility Surging for Amarin (AMRN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Amarin (AMRN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Amarin (AMRN) closed at $6.92, marking a +0.58% move from the previous day.
Amarin (AMRN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Amarin (AMRN) closed at $6.78 in the latest trading session, marking a +0.89% move from the prior day.
Amarin (AMRN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Amarin (AMRN) closed the most recent trading day at $6.59, moving -1.35% from the previous trading session.
Why Amarin (AMRN) Stock Might be a Great Pick
by Zacks Equity Research
Amarin (AMRN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Amarin (AMRN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Amarin (AMRN) closed at $6.68, marking a -1.18% move from the previous day.
Ultragenyx (RARE) Q1 Earnings & Sales Fall Short of Estimates
by Zacks Equity Research
Ultragenyx (RARE) reports wider-than-expected first-quarter 2020 loss.
Iovance (IOVA) Q1 Loss Wider Than Expected, Revenues Nil
by Zacks Equity Research
Iovance's (IOVA) first-quarter loss wider than estimated. The company progressing well with its lead pipeline candidates.
Amarin's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Amarin.